Highlights
- The recent 2026 multicenter RCT (Meerman et al.) was stopped early for futility, showing no reduction in postoperative atrial fibrillation (POAF) despite achieving target magnesium levels of 1.5–2.0 mmol/L.
- Large-scale clinical evidence indicates that magnesium supplementation provides no additional benefit in patients already receiving standard postoperative beta-blocker therapy.
- While some smaller studies in off-pump coronary artery bypass grafting (OP-CABG) suggest efficacy, broader meta-analyses do not support routine intraoperative or postoperative magnesium as a primary prevention strategy.
- Observational data have linked magnesium administration with an paradoxically increased risk of AF in certain critical care settings, highlighting the complexity of electrolyte management.
Background
Postoperative atrial fibrillation (POAF) remains the most frequent complication following cardiac surgery, occurring in 20% to 40% of patients. It is associated with hemodynamic instability, increased risk of stroke, prolonged hospital stay, and higher healthcare costs. Hypomagnesemia is common following cardiopulmonary bypass (CPB) due to hemodilution and urinary losses. Given magnesium’s role as a natural calcium channel blocker and its ability to prolong the atrial refractory period, it has been hypothesized for decades that magnesium supplementation could serve as a low-cost, low-risk prophylactic measure. However, despite its widespread use in clinical practice, the evidence supporting its efficacy has remained inconsistent, with conflicting results between small-scale trials and large randomized controlled trials (RCTs).
Key Content
The Shifting Paradigm: From Early Promise to Futility
Historically, small trials and early meta-analyses suggested that magnesium could reduce POAF incidence. However, as trial methodologies have matured, the signal of benefit has weakened.
In a landmark RCT published in 2026 (Meerman et al., PMID: 42206948), researchers conducted a double-blind, placebo-controlled trial at HagaZiekenhuis, targeting high serum magnesium concentrations of 1.5–2.0 mmol/L. The study was halted after an interim analysis of 265 patients revealed futility. The magnesium group actually had a numerically higher incidence of POAF (37.9%) compared to the placebo group (28.6%), with a relative risk of 1.29. This trial specifically addressed the question of whether maintaining higher-than-normal serum levels provides protection, concluding definitively that it does not.
This mirrors findings from earlier major studies, such as the 2009 Circulation trial (PMID: 19752363), which enrolled 927 patients. This study found that adding prophylactic IV magnesium to an established oral beta-blocker protocol provided no further reduction in atrial arrhythmias.
Meta-Analytic Evidence and Subgroup Variations
A 2019 systematic review and meta-analysis of 20 RCTs (N=2,430) provided a nuanced view (PMID: 31687067). While the pooled analysis showed no overall reduction in POAF (RR 0.90; p=0.13), a subgroup analysis indicated that *postoperative* magnesium supplementation might offer a modest benefit (RR 0.76; p=0.04), whereas intraoperative-only or combined regimens did not.
Magnesium in Specialized Contexts: Off-Pump and Cardioplegia
Interestingly, evidence remains more positive in the subset of off-pump coronary artery bypass grafting (OP-CABG). A 2025 study (PMID: 40629782) found that a magnesium infusion (targeting 1.5-2 mmol/L) significantly reduced POAF incidence (1.9% vs 19.2%, p=0.008) in OP-CABG patients. This suggests that the impact of magnesium might be influenced by the presence or absence of cardiopulmonary bypass and the associated inflammatory response.
Furthermore, magnesium’s role in cardioplegic solutions has been explored. Studies comparing del Nido cardioplegia (which contains magnesium) to Buckberg solutions found a lower incidence of POAF in the del Nido groups (PMID: 39730296). Another trial showed that high-dose magnesium in cardioplegic solutions (80-100 mg/kg) was more effective at reducing AF than lower doses (60 mg/kg) (PMID: 27225338).
Comparative and Combination Therapies
Researchers have also compared magnesium to other antiarrhythmics or investigated combinations:
- Dexmedetomidine vs. Magnesium: Magnesium sulfate was found to be more effective than dexmedetomidine at preventing arrhythmias, with a better safety profile regarding hypotension and bradycardia (PMID: 37519545).
- Combination Therapy: The addition of amiodarone or diltiazem to magnesium does not appear to provide a synergistic reduction in POAF incidence compared to magnesium alone (PMID: 37861573).
Expert Commentary
The divergence in clinical findings—ranging from high efficacy in some studies to futility in others—likely stems from several variables: background beta-blocker use, the timing of magnesium administration, and the specific surgical population.
When patients are already optimized on beta-blockers, the additional electrophysiological benefit of magnesium is marginal. Mechanistically, magnesium’s role as a calcium antagonist is well-understood, but its osmotic effects and potential for inducing vasodilation may necessitate increased vasopressor support, as noted in the Meerman study. Furthermore, observational data (PMID: 31948890) have even suggested that magnesium administration can be associated with an *increased* risk of AF, potentially due to confounding factors where sicker patients with higher baseline risk are more likely to receive electrolytes.
Recent feasibility studies (e.g., PROSPECTOR, PMID: 40348398) demonstrate that digital integration of research into electronic patient records (EPRs) is the future of solving these controversies, allowing for high-fidelity, real-world comparative effectiveness trials.
Conclusion
While magnesium supplementation remains a common practice in cardiac surgery due to its low cost and perceived safety, current high-quality evidence from the 2026 Meerman trial and others does not support its routine use for the primary prevention of POAF. The targeting of high-normal serum magnesium levels appears futile in reducing the incidence of de novo atrial fibrillation. Clinicians should focus on established strategies, such as the perioperative use of beta-blockers, and reserve magnesium for the correction of overt hypomagnesemia rather than as a prophylactic antiarrhythmic. Future research should prioritize identifying specific patient phenotypes (e.g., OP-CABG) where a benefit might still exist and optimizing digital trial infrastructures to provide definitive real-world answers.
References
- Meerman M, et al. Magnesium Sulfate to Prevent Perioperative Atrial Fibrillation in Cardiac Surgery: A Randomized Clinical Trial. Crit Care Med. 2026. PMID: 42206948.
- Cook JL, et al. Results of the PROSPECTOR randomised feasibility study. BMJ Evid Based Med. 2025. PMID: 40348398.
- Wu X, et al. Role of Prophylactic Magnesium Supplementation in Prevention of POAF: a Systematic Review and Meta-Analysis of 20 RCTs. J Atr Fibrillation. 2019. PMID: 31687067.
- Dorian P, et al. Prophylactic IV magnesium sulphate does not prevent atrial arrhythmias after cardiac surgery: a randomized, controlled trial. Circulation. 2009. PMID: 19752363.
